NO20050649L - Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse derav - Google Patents
Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse deravInfo
- Publication number
- NO20050649L NO20050649L NO20050649A NO20050649A NO20050649L NO 20050649 L NO20050649 L NO 20050649L NO 20050649 A NO20050649 A NO 20050649A NO 20050649 A NO20050649 A NO 20050649A NO 20050649 L NO20050649 L NO 20050649L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- thiophenyl
- new
- medicaments
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10231370A DE10231370B4 (de) | 2002-07-11 | 2002-07-11 | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| PCT/EP2003/006841 WO2004007517A1 (de) | 2002-07-11 | 2003-06-27 | Neue thiophenglycosidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050649L true NO20050649L (no) | 2005-04-01 |
Family
ID=30009905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050649A NO20050649L (no) | 2002-07-11 | 2005-02-07 | Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse derav |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US7101856B2 (el) |
| EP (4) | EP1523488B1 (el) |
| JP (1) | JP4511927B2 (el) |
| KR (1) | KR20050021452A (el) |
| CN (2) | CN101240000A (el) |
| AR (1) | AR040474A1 (el) |
| AT (4) | ATE477266T1 (el) |
| AU (1) | AU2003246620B2 (el) |
| BR (1) | BR0312513A (el) |
| CA (1) | CA2493391C (el) |
| CR (1) | CR7718A (el) |
| CY (1) | CY1108754T1 (el) |
| DE (5) | DE10231370B4 (el) |
| DK (1) | DK1523488T3 (el) |
| EC (1) | ECSP055531A (el) |
| ES (1) | ES2316818T3 (el) |
| HK (1) | HK1080482A1 (el) |
| HN (1) | HN2003000215A (el) |
| HR (1) | HRP20050014A2 (el) |
| IL (2) | IL166058A0 (el) |
| JO (1) | JO2707B1 (el) |
| MA (1) | MA27366A1 (el) |
| ME (1) | MEP60708A (el) |
| MX (1) | MXPA05000044A (el) |
| MY (1) | MY137039A (el) |
| NO (1) | NO20050649L (el) |
| OA (1) | OA12880A (el) |
| PA (1) | PA8577101A1 (el) |
| PE (1) | PE20040655A1 (el) |
| PL (1) | PL372931A1 (el) |
| PT (1) | PT1523488E (el) |
| RS (1) | RS51002B (el) |
| RU (1) | RU2317300C2 (el) |
| SI (1) | SI1523488T1 (el) |
| TN (1) | TNSN05007A1 (el) |
| TW (1) | TWI318981B (el) |
| UA (1) | UA78823C2 (el) |
| UY (1) | UY27891A1 (el) |
| WO (1) | WO2004007517A1 (el) |
| ZA (1) | ZA200409779B (el) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7439232B2 (en) | 2003-04-01 | 2008-10-21 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
| ME00411B (me) | 2003-08-01 | 2011-10-10 | Tanabe Seiyaku Co | Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma |
| US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| DE102004063099B4 (de) * | 2004-12-22 | 2009-02-12 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Thiophenglycosidderivaten |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| TWI365186B (en) | 2005-01-31 | 2012-06-01 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| JP5063581B2 (ja) | 2005-03-23 | 2012-10-31 | アクテリオン ファーマシューティカルズ リミテッド | 新規チオフェン誘導体 |
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
| MX2007016505A (es) * | 2005-06-24 | 2008-03-07 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno. |
| KR20080092385A (ko) | 2006-01-24 | 2008-10-15 | 액테리온 파마슈티칼 리미티드 | 신규한 피리딘 유도체 |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| TWI432446B (zh) | 2006-07-27 | 2014-04-01 | Chugai Pharmaceutical Co Ltd | 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用 |
| TWI418556B (zh) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| JPWO2008044762A1 (ja) | 2006-10-13 | 2010-02-18 | 中外製薬株式会社 | チオグルコーススピロケタール誘導体、およびその糖尿病治療薬としての使用 |
| JP5298025B2 (ja) | 2006-12-04 | 2013-09-25 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体 |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| RS56990B1 (sr) | 2007-09-10 | 2018-05-31 | Janssen Pharmaceutica Nv | Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| WO2009138195A2 (en) * | 2008-05-16 | 2009-11-19 | Sanofi-Aventis Deutschland Gmbh | Use of thiophene glycoside derivatives for producing medicaments for treatment of hypertension |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| EA018492B1 (ru) * | 2008-08-28 | 2013-08-30 | Пфайзер Инк. | Диоксабицикло[3.2.1]октан-2,3,4-триольные производные |
| US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| SI2395983T1 (sl) | 2009-02-13 | 2020-08-31 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, ki obsega SGLT2 inhibitor, DPP-IV inhibitor in po izbiri nadaljnje antidiabetično sredstvo in uporabe le-teh |
| US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| PL2451797T3 (pl) | 2009-07-10 | 2013-08-30 | Janssen Pharmaceutica Nv | Proces krystalizacji dla 1-(ß-D-glukopiranozylo)-4-metylo-3-[5-(4-fluorofenylo)-2-tienylometylo]benzenu |
| US8785608B2 (en) | 2009-08-26 | 2014-07-22 | Sanofi | Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| IN2012DN02751A (el) | 2009-09-30 | 2015-09-18 | Boehringer Ingelheim Int | |
| HUE029381T2 (en) | 2009-09-30 | 2017-02-28 | Boehringer Ingelheim Int | A method for preparing a crystalline form of 1-chloro-4- (beta-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) benzyl] benzene. |
| UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| WO2011047113A1 (en) | 2009-10-14 | 2011-04-21 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| CA2778384A1 (en) | 2009-10-20 | 2011-04-28 | Novartis Ag | Glycoside derivative and uses thereof |
| GEP20146104B (en) | 2009-11-02 | 2014-05-27 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2552442A1 (en) | 2010-03-30 | 2013-02-06 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| BR112012028857B1 (pt) | 2010-05-11 | 2021-02-09 | Janssen Pharmaceutica Nv | Composições farmacêuticas administráveis por via oral que compreendem derivados de 1- (beta-d glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20120276108A1 (en) * | 2011-01-11 | 2012-11-01 | Intertech Bio | Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120057A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| CN103596944B (zh) | 2011-04-13 | 2017-02-22 | 詹森药业有限公司 | 可用作sglt2的抑制剂的化合物的制备方法 |
| BR112013026361A2 (pt) | 2011-04-14 | 2016-12-27 | Novartis Ag | derivados de glicosídeo e usos dos mesmos |
| US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| MX2013014135A (es) | 2011-06-03 | 2014-01-23 | Boehringer Ingelheim Int | Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos. |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
| US9573959B2 (en) | 2013-03-14 | 2017-02-21 | Msd International Gmbh | Methods for preparing SGLT2 inhibitors |
| HUE064190T2 (hu) | 2013-04-04 | 2024-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Lófélék anyagcserezavarainak kezelése |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| EP3939595A1 (en) | 2013-04-05 | 2022-01-19 | Board of Regents, The University of Texas System | Esters of 2-deoxy-monosaccharides with anti proliferative activity |
| CN105377266A (zh) | 2013-04-18 | 2016-03-02 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
| CA3163455A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
| SI3485890T1 (sl) | 2014-01-23 | 2023-09-29 | Boehringer Ingelheim Vetmedica Gmbh | Inhibitorji SGLT2 za zdravljenje presnovnih motenj pri pasjih živalih |
| HUE050095T2 (hu) | 2014-04-01 | 2020-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Anyagcsere-rendellenességek kezelése lófélékben |
| EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
| CN104478966A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| CN104478968A (zh) * | 2015-01-14 | 2015-04-01 | 佛山市赛维斯医药科技有限公司 | 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| CN109843279A (zh) | 2016-10-19 | 2019-06-04 | 勃林格殷格翰国际有限公司 | 包含ssao/vap-1抑制剂和sglt2抑制剂的药物组合、其用途 |
| CN111989103A (zh) | 2018-04-17 | 2020-11-24 | 勃林格殷格翰国际有限公司 | 药物组合物、其治疗方法和用途 |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| UY38969A (es) | 2019-11-28 | 2021-05-31 | Boehringer Ingelheim Vetmedica Gmbh | Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos |
| EP4106744A1 (en) | 2020-02-17 | 2022-12-28 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
| AU2022318037A1 (en) | 2021-07-28 | 2024-02-22 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
| EP4376819A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| KR20240041966A (ko) | 2021-07-28 | 2024-04-01 | 베링거잉겔하임베트메디카게엠베하 | 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도 |
| WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
| WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA165448A (en) | 1914-10-23 | 1915-10-12 | Otto F. Hornschuch | Ironing board |
| FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| CN1158290C (zh) | 1996-01-17 | 2004-07-21 | 诺沃挪第克公司 | 稠合1,2,4-噻二嗪与稠合1,4-噻嗪衍生物、其制备方法及用途 |
| WO1997041097A2 (en) | 1996-12-31 | 1997-11-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| BRPI9711437B8 (pt) | 1996-08-30 | 2021-05-25 | Novo Nordisk As | derivados de glp-1 |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| BR9810592A (pt) | 1997-07-16 | 2000-09-12 | Novo Nordisk As | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto |
| CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| BR0010605A (pt) | 1999-04-28 | 2002-02-13 | Aventis Pharma Gmbh | Derivados ácidos de di-aril como ligantes de receptores ppar |
| BR0010126A (pt) | 1999-04-28 | 2002-02-26 | Aventis Pharma Gmbh | Derivados de ácido tri-arìlico como ligandos receptores de ppar |
| CA2371271A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands |
| GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
| AU773505B2 (en) | 1999-06-18 | 2004-05-27 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
| BR0012752A (pt) | 1999-07-29 | 2002-04-02 | Lilly Co Eli | Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina |
| US6324512B1 (en) | 1999-08-26 | 2001-11-27 | Matsushita Electric Industrial Co., Ltd. | System and method for allowing family members to access TV contents and program media recorder over telephone or internet |
| CN1145635C (zh) * | 1999-08-31 | 2004-04-14 | 橘生药品工业株式会社 | 吡喃葡糖氧基吡唑衍生物、含该衍生物的药物组合物及其制备中的中间体 |
| CA2407538C (en) | 2000-04-28 | 2007-01-09 | Asahi Kasei Kabushiki Kaisha | Novel bicyclic compounds |
| EP1280777B1 (en) | 2000-05-11 | 2005-11-23 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
-
2002
- 2002-07-11 DE DE10231370A patent/DE10231370B4/de not_active Expired - Fee Related
-
2003
- 2003-06-23 JO JOP/2003/0068A patent/JO2707B1/ar active
- 2003-06-27 DE DE50312984T patent/DE50312984D1/de not_active Expired - Lifetime
- 2003-06-27 DE DE50310783T patent/DE50310783D1/de not_active Expired - Lifetime
- 2003-06-27 JP JP2004520429A patent/JP4511927B2/ja not_active Expired - Fee Related
- 2003-06-27 ES ES03763662T patent/ES2316818T3/es not_active Expired - Lifetime
- 2003-06-27 ME MEP-607/08A patent/MEP60708A/xx unknown
- 2003-06-27 WO PCT/EP2003/006841 patent/WO2004007517A1/de active Application Filing
- 2003-06-27 DE DE50313056T patent/DE50313056D1/de not_active Expired - Lifetime
- 2003-06-27 PT PT03763662T patent/PT1523488E/pt unknown
- 2003-06-27 AT AT08008232T patent/ATE477266T1/de active
- 2003-06-27 CA CA2493391A patent/CA2493391C/en not_active Expired - Fee Related
- 2003-06-27 UA UAA200501215A patent/UA78823C2/uk unknown
- 2003-06-27 PL PL03372931A patent/PL372931A1/xx not_active Application Discontinuation
- 2003-06-27 EP EP03763662A patent/EP1523488B1/de not_active Expired - Lifetime
- 2003-06-27 MX MXPA05000044A patent/MXPA05000044A/es active IP Right Grant
- 2003-06-27 SI SI200331500T patent/SI1523488T1/sl unknown
- 2003-06-27 AT AT03763662T patent/ATE414095T1/de not_active IP Right Cessation
- 2003-06-27 RS YUP-1150/04A patent/RS51002B/sr unknown
- 2003-06-27 EP EP08008079A patent/EP1964844B1/de not_active Expired - Lifetime
- 2003-06-27 BR BR0312513-0A patent/BR0312513A/pt not_active IP Right Cessation
- 2003-06-27 AU AU2003246620A patent/AU2003246620B2/en not_active Ceased
- 2003-06-27 DE DE50312983T patent/DE50312983D1/de not_active Expired - Lifetime
- 2003-06-27 KR KR10-2005-7000500A patent/KR20050021452A/ko not_active Application Discontinuation
- 2003-06-27 AT AT08008079T patent/ATE479697T1/de active
- 2003-06-27 DK DK03763662T patent/DK1523488T3/da active
- 2003-06-27 CN CNA2008100828971A patent/CN101240000A/zh active Pending
- 2003-06-27 OA OA1200500001A patent/OA12880A/en unknown
- 2003-06-27 RU RU2005103602/04A patent/RU2317300C2/ru not_active IP Right Cessation
- 2003-06-27 AT AT08009226T patent/ATE477265T1/de active
- 2003-06-27 EP EP08009226A patent/EP1964845B1/de not_active Expired - Lifetime
- 2003-06-27 CN CNB038165325A patent/CN100384863C/zh not_active Expired - Fee Related
- 2003-06-27 EP EP08008232A patent/EP1967523B1/de not_active Expired - Lifetime
- 2003-07-08 AR AR20030102456A patent/AR040474A1/es unknown
- 2003-07-09 TW TW092118657A patent/TWI318981B/zh active
- 2003-07-09 PE PE2003000688A patent/PE20040655A1/es not_active Application Discontinuation
- 2003-07-10 HN HN2003000215A patent/HN2003000215A/es unknown
- 2003-07-10 PA PA20038577101A patent/PA8577101A1/es unknown
- 2003-07-10 MY MYPI20032596A patent/MY137039A/en unknown
- 2003-07-11 US US10/616,945 patent/US7101856B2/en not_active Expired - Lifetime
- 2003-07-11 UY UY27891A patent/UY27891A1/es unknown
-
2004
- 2004-12-02 ZA ZA200409779A patent/ZA200409779B/en unknown
- 2004-12-14 MA MA28004A patent/MA27366A1/fr unknown
- 2004-12-23 IL IL16605804A patent/IL166058A0/xx not_active IP Right Cessation
-
2005
- 2005-01-10 TN TNP2005000007A patent/TNSN05007A1/en unknown
- 2005-01-10 HR HR20050014A patent/HRP20050014A2/hr not_active Application Discontinuation
- 2005-01-11 EC EC2005005531A patent/ECSP055531A/es unknown
- 2005-02-07 NO NO20050649A patent/NO20050649L/no unknown
- 2005-03-07 CR CR7718A patent/CR7718A/es not_active Application Discontinuation
-
2006
- 2006-01-10 HK HK06100362A patent/HK1080482A1/xx not_active IP Right Cessation
- 2006-08-14 US US11/464,338 patent/US7666848B2/en not_active Expired - Fee Related
-
2008
- 2008-06-03 IL IL191926A patent/IL191926A0/en unknown
-
2009
- 2009-02-05 CY CY20091100138T patent/CY1108754T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050649L (no) | Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse derav | |
| NO20070176L (no) | Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav | |
| NO20044882L (no) | Acyl-4-karboksylfenylurinstoffderivater, deres fremstilling og anvendelse | |
| NO20091893L (no) | Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav. | |
| NO20053201L (no) | Nye heterocykliske fluorglukosidderivater, legemidler inneholdende disse forbindelser og deres anvendelse. | |
| NO20071593L (no) | Pyrimidinderivater | |
| NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
| NO20056132L (no) | Krystallinsk form av beta2 adrenergisk receptoragonist | |
| NO20062020L (no) | 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika | |
| NO20076460L (no) | Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav | |
| BRPI0508098A (pt) | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos | |
| SE0202463D0 (sv) | Novel compounds | |
| BRPI0514537B8 (pt) | compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende | |
| NO20071137L (no) | Nye piperidinderivater for behandling av depresjon | |
| SG151254A1 (en) | Substituted morpholine and thiomorpholine derivatives | |
| NO20084129L (no) | Pyridin(3,4-B)Pyrazinoner | |
| UA99617C2 (ru) | Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение | |
| NO20050134L (no) | Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse | |
| NO20076695L (no) | Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser | |
| NO20062491L (no) | Benzoksazinderivter og deres anvendelse | |
| CR8360A (es) | 1,3 dimetilbutilcarboxanilidas | |
| NO20072005L (no) | Nye heterocykliske amider | |
| NO20076680L (no) | Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter | |
| NO20065073L (no) | Nye beta-agonister, metoder for deres fremstilling og deres anvendelse som medikamenter. | |
| NO20090332L (no) | 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler |